Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Commercial Companies Vaccines

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Business Strategies Companies Research & Development

FDA Leader: We Need To Remove Surprises From Gene Therapy Development

Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market.

Commercial Companies Regulation

Asia Spotlight

How Ex-Janssen India Chief Is Steering Bharat Serums’ Ambitions In Women’s Health

Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health  -  it goes beyond  drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.


Commercial India

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D,

deal-making and business strategy developments.

More Podcasts


Recent Tweets from Scrip


 

Infographics

Who Were Big Pharma's Top Deal-Makers In 2021?

INFOGRAPHIC: Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.

Deals M & A

Bugs As Drugs: The Budding Microbiome Modulator Pipeline

INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

Infectious Diseases Companies

Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Commercial Financing

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Orphazyme’s Sorry Story Ends In Fire Sale

While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Neimann-Pick disease type C.

M & A Rare Diseases

Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty

The first COVID-19 vaccine to be approved, Sputnik V, faced production issues soon after, but a solution was found with Sputnik Light. Now, data indicate manufacturing partners in India, China, Korea and other countries could be left holding unsold inventory earmarked for exports as high vaccination numbers will mean limited scope for domestic supplies

Commercial Coronavirus COVID-19

Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation

Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US. 

Financing Strategy

Can Roche’s Phesgo Mirror UK Adoption Trend in India?

Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?

Commercial Pricing Strategies

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

Deal Watch Business Strategies

AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

Deals Infectious Diseases
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx

The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.

Complete Response Letters Immune Disorders

Lecanemab Filing Complicates Biogen's Hunt For New CEO

Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.

Neurology Commercial

Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen

Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab. 

Business Strategies Neurology
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

Ocuphire Chalks Up Another Phase III Success For Nyxol

The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.

Business Strategies Ophthalmic

Enanta’s Path Forward Uncertain After RSV Failure

The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.

Clinical Trials Respiratory

Trial Hot Spot: Australia's Attractions To The Korean Industry

Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.

Australia Clinical Trials
See All
UsernamePublicRestriction

Register